

10-3-3



FSUM 10466.59  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit 1625

Application of Robert A. Holton  
Serial No. 10/606,027  
Filed June 25, 2003  
Confirmation No. To Be Assigned  
For C7 ESTER SUBSTITUTED TAXANES  
Examiner Ba K. Trinh

October 2, 2003

TO THE COMMISSIONER FOR PATENTS,  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

SIR:

**INFORMATION DISCLOSURE STATEMENT**

\* In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. Copies of the references cited have not been provided in accordance with 37 C.F.R. § 1.98(d) because they are of record in prior application Serial No. 09/775,851, filed February 2, 2001, now U.S. Patent 6,610,860 B2, relied upon for an earlier filing date under 35 U.S.C. § 120.

Respectfully submitted,




Edward J. Hejlek, Reg. No. 31,525  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

EJH/JSH/dfw  
\*Attachment

Express Mail Label No. EV 272754522 US

PTO/SB/08A

OCT 02 2003



**FIFTH SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

<p><b>FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Application Number	10/606,027
				Filing Date	June 25, 2003
				Confirmation Number	To Be Assigned
				First Named Inventor	Robert A. Holton
				Group Art Unit	1625
				Examiner Name	Ba K. Trinh
Sheet	1	of	5	Attorney Docket No.	FSUM 10466.59

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1.	4,960,790		Stella et al.	10-02-1990
	2.	5,175,315		Holton	12-29-1992
	3.	5,200,534		Rao	04-06-1993
	4.	5,227,400		Holton et al.	07-13-1993
	5.	5,243,045		Holton et al.	09-07-1993
	6.	5,248,796		Chen et al.	09-28-1993
	7.	5,283,253		Holton et al.	02-01-1994
	8.	5,319,112		Kingston et al.	06-07-1994
	9.	5,350,866		Holton et al.	09-27-1994
	10.	5,352,806		Gunawardana et al.	10-04-1994
	11.	5,415,869		Straubinger et al.	05-16-1995
	12.	5,422,364		Nicolaou et al.	06-06-1995
	13.	5,430,160		Holton	07-04-1995
	14.	5,489,601		Holton et al.	02-06-1996
	15.	5,530,020		Gunawardana et al.	06-25-1996
	16.	5,567,614		Patel et al.	10-22-1996

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**FIFTH SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/606,027
Filing Date	June 25, 2003
Confirmation Number	To Be Assigned
First Named Inventor	Robert A. Holton
Group Art Unit	1625
Examiner Name	Ba K. Trinh
Attorney Docket No.	FSUM 10466.59

Sheet **2** of **5**

17.	5,614,645	Kingston et al.	03-25-1997
18.	5,714,513	Holton et al.	02-03-1998
19.	5,721,268	Holton et al.	02-24-1998
20.	5,767,297	Mandai et al.	06-16-1998
21.	5,780,653	Tao et al.	07-14-1998
22.	5,811,452	Ojima et al.	09-22-1998
23.	5,879,929	Patel	03-09-1999
24.	5,912,264	Wittman et al.	06-15-1999
25.	5,965,739	Kelly et al.	10-12-1999
26.	6,136,988	Murray et al.	10-24-2000
27.	US 2001/0002404 A1	Webb et al.	05-31-2001

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
	28.	EP	0 590 267	A2	Bristol-Myers Squibb Co.	04-06-1994	
	29.	EP	0 629 701	B1	Bristol-Myers Squibb Co.	12-21-1994	
	30.	EP	0 558 959	B1	Bristol-Myers Squibb Co.	09-08-1993	
	31.	EP	0 747 385	B1	Bristol-Myers Squibb Co.	08-14-2002	
	32.	WO	90/10443	A1	University of Kansas	09-20-1990	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

# **FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)



## **Complete if Known**

Application Number	10/606,027
Filing Date	June 25, 2003
Confirmation Number	To Be Assigned
First Named Inventor	Robert A. Holton
Group Art Unit	1625
Examiner Name	Ba K. Trinh
Attorney Docket No.	FSUM 10466.59

Sheet

3

5

	33.	WO	93/02065	A1	Rhone Poulenc Rorer	02-04-1993	
	34.	WO	94/14787	A1	Bristol-Myers Squibb Co.	07-07-1994	
	35.	WO	95/11241	A1	Rhone-Poulenc Rorer, S.A.	04-27-1995	
	36.	WO	95/13053	A1	The Research Foundation of State University of New York	05-18-1995	
	37.	WO	97/09979	A1	Florida State University	03-20-1997	
	38.	WO	97/42181	A1	Florida State University	11-13-1997	
	39.	WO	97/44026	A1	Neuromedica, Inc.	11-27-1997	
	40.	WO	97/44063	A2	Neuromedica, Inc.	11-27-1997	
	41.	WO	99/09021	A1	Florida State University	02-25-1999	
	42.	WO	00/01366	A1	Neopharm	01-13-2000	
	43.	WO	00/78707	A1	Napro Biotherapeutics, Inc.	12-28-2000	
	44.	WO	01/25223	A1	The Research Foundation of State University of New York	04-12-2001	
	45.	WO	01/57013	A1	Florida State University Research Foundation, Inc.	08-09-2001	
	46.	WO	01/57027	A1	Florida State University Research Foundation, Inc.	08-09-2001	
	47.	WO	01/68089	A1	Indena SPA	09-20-2001	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**FIFTH SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Compleat if Known**

Application Number	10/606,027
Filing Date	June 25, 2003
Confirmation Number	To Be Assigned
First Named Inventor	Robert A. Holton
Group Art Unit	1625
Examiner Name	Ba K. Trinh
Attorney Docket No.	FSUM 10466.59

Sheet

4

of

5

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	48.	DEUTSCH et al. "Synthesis of Congeners and Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity" Journal of Medicinal Chemistry, Vol. 32, No. 4 (1989) pp. 788-792.	
	49.	DUBOIS et al. "Fluorescent and Biotinylated Analogues of Docetaxel: Synthesis and Biological Evaluation" Bioorganic & Medicinal Chemistry, Vol. 3, No. 10 (1995) pp. 1357-1368.	
	50.	European Search Report for EP 01 10 2160 dated July 9, 2001.	
	51.	FERLINI et al. "Antitumor Activity of Novel Taxanes that Act at the Same Time as Cytotoxic Agents and P-Glycoprotein Inhibitors" British Journal of Cancer, Vol. 83, No. 12 (2000) pp. 1762-1768.	
	52.	GUENARD et al. "Effects of the Hydrophobicity of Taxoids on their Interaction with Tubulin" Bioorganic & Medicinal Chemistry, Vol. 8 (2000) pp. 145-156.	
	53.	GUERITTE-VOEGELEIN et al. "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity" Journal of Medicinal Chemistry, Vol. 34, No. 3 (1991) pp. 992-998.	
	54.	International Search Report for analogous PCT Application No. PCT/US01/03385 dated June 11, 2001.	
	55.	ISHIHARA et al. "Scandium Trifluoromethanesulfonate as an Extremely Active Acylation Catalyst" J. Am. Chem. Soc., Vol. 117, No. 15 (1995) pp. 4413-4414.	
	56.	KINGSTON et al. "The Chemistry of Taxol, A Clinically Useful Anticancer Agent" Journal of Natural Products, Vol. 53, No. 1 (1990) pp. 1-12.	
	57.	KLEIN "Synthesis of 9-Dihydrotaxol: A Novel Bioactive Taxane" Tetrahedron Letters, Vol. 34, No. 13 (1993) pp. 2047-2050.	
	58.	LIANG et al. "Synthesis and Biological Evaluation of Paclitaxel Analogs Modified in Ring C" Tetrahedron Letters, Vol. 36, No. 17 (1995) pp. 2901-2904.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				<b>Complete if Known</b>	
<p style="text-align: center;"><b>FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p style="text-align: center;">(use as many sheets as necessary)</p>				Application Number	10/606,027
				Filing Date	June 25, 2003
				Confirmation Number	To Be Assigned
				First Named Inventor	Robert A. Holton
				Group Art Unit	1625
				Examiner Name	Ba K. Trinh
Sheet	5	of	5	Attorney Docket No.	FSUM 10466.59

59.	MELLADO et al. "Preparation and Biological Activity of Taxol Acetates" Biochemical and Biophysical Research Communications, Vol. 124, No. 2 (1984) pp. 329-336.	
60.	OJIMA et al. "New Photoaffinity Analogs of Paclitaxel" Bioorganic & Medicinal Chemistry Letters, Vol. 9 (1999) pp. 1189-1194.	
61.	PATEL "Tour De Paclitaxel: Biocatalysis for Semisynthesis" Annu. Rev. Microbiol. Vol. 52 (1998) pp. 361-395.	
62.	SHI et al. "Studies on the Quantitative Structure-Activity Relationships of Paclitaxel Analogues" GAODENG, XUOXIAO, HUAXUE XUEBAO, Vol. 21, No. 3 (2000) pp. 401-406.	
63.	STRAUBINGER et al. "Pharmacology and Antitumor Effect of Novel Paclitaxel Formulations" Chapter 8, Edited by G. Georg et al., Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583, 207th National Meeting of the American Chemical Society, San Diego, CA (1994) pp. 111-123.	
64.	SUFFNESS "Chapter 32. Taxol: From Discovery to Therapeutic Use" Annual Reports in Medicinal Chemistry, Vol. 28 (1993) pp. 305-314.	
65.	VYAS et al. "Phosphatase-Activated Prodrugs of Paclitaxel" Chapter 9, Edited by G. Georg et al., Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583, 207th National Meeting of the American Chemical Society, San Diego, CA (1994) pp. 124-137.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.